Early Experience of High-dose Intravenous in Critically Ill Patients of COVID-19.

BACKGROUND

Immune dysregulation is one of the main reasons for mortality and morbidity in coronavirus disease 2019 (COVID-19). Mycobacterium w (Mw) is recently approved for gram-negative sepsis. Moreover, it is also found effective in COVID-19 patients in previous studies. The traditional route of administration for Mw is intradermal, which has a limitation of administering 0.1 mL per injection and local injection site reaction. Intravenous (IV) administration of Mw has not been explored in COVID-19. We report the retrospective analysis of six critically ill COVID-19 patients who received Mw (IV).

PATIENTS AND METHODS

At baseline, all patients in this case series required O supplementation, and their inflammatory biomarkers were elevated. All patients received 0.6 mL Mw (high-dose) in normal saline along with the standard-of-care treatment.

RESULTS

After Mw administration, gradual improvement in O requirement was observed and patients were discharged from the hospital with no mortality. A reduction in mean C-reactive protein (CRP) (51.48-18.52 mg/dL), interleukin-6 (IL-6) (260.22-14.47 pg/mL), and FiO (81.67-43.33) was also observed. No side effects were observed with the use of Mw by IV route.

CONCLUSION

Use of 0.6 mL Mw by IV route in this case series was associated with decreased O supplementation without any side effects in critically ill patients of COVID-19.

HOW TO CITE THIS ARTICLE

Patel PS, Patel S, Shah V, Aswani V, Narwaria M. Early Experience of High-dose Intravenous in Critically Ill Patients of COVID-19. Indian J Crit Care Med 2021;25(9):1066-1068.